AVLN - Latest News
Avalyn Pharma Inc. Common Stock (AVLN), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.54B. Beta to the broader market is -1.13.
The article list below shows the most recent AVLN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent AVLN Headlines
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
globenewswire.com - Aug 24, 2026
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations de
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com - Aug 12, 2026
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
globenewswire.com - Jun 17, 2026
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
marketbeat.com - Jun 5, 2026
Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphas
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com - Jun 3, 2026
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term ope
How News Affects AVLN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AVLN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked AVLN news questions
- What is the latest AVLN news headline?
- The most recent AVLN headline (Aug 24, 2026) is "Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the AVLN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What AVLN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual AVLN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.